Leerink Swann reiterated their outperform rating on shares of American Renal Associates Holdings, Inc (NYSE:ARA) in a report released on Tuesday morning, The Fly reports. The brokerage currently has a $17.00 price target on the stock, down from their previous price target of $22.00. Leerink Swann also issued estimates for American Renal Associates Holdings’ Q4 2017 earnings at $0.18 EPS, FY2017 earnings at $0.59 EPS, FY2018 earnings at $0.79 EPS, FY2019 earnings at $0.93 EPS and FY2020 earnings at $1.06 EPS.

A number of other research firms also recently commented on ARA. Zacks Investment Research downgraded shares of American Renal Associates Holdings from a buy rating to a hold rating in a research note on Friday, November 17th. SunTrust Banks, Inc. set a $18.00 price objective on shares of American Renal Associates Holdings and gave the company a buy rating in a research note on Sunday, October 15th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. American Renal Associates Holdings has a consensus rating of Buy and an average price target of $17.75.

American Renal Associates Holdings (NYSE:ARA) opened at $13.38 on Tuesday. American Renal Associates Holdings has a one year low of $9.91 and a one year high of $24.94. The company has a current ratio of 1.16, a quick ratio of 1.13 and a debt-to-equity ratio of 3.57. The company has a market cap of $412.14, a PE ratio of 19.55, a PEG ratio of 1.16 and a beta of 3.64.

American Renal Associates Holdings (NYSE:ARA) last posted its quarterly earnings data on Tuesday, November 14th. The company reported $0.19 EPS for the quarter, beating the Zacks’ consensus estimate of $0.16 by $0.03. American Renal Associates Holdings had a negative net margin of 2.15% and a positive return on equity of 15.80%. The company had revenue of $187.71 million during the quarter, compared to the consensus estimate of $194.60 million. During the same quarter in the prior year, the company posted $0.28 EPS. The company’s quarterly revenue was down 2.7% compared to the same quarter last year. sell-side analysts forecast that American Renal Associates Holdings will post 0.57 earnings per share for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of ARA. Vanguard Group Inc. increased its position in American Renal Associates Holdings by 11.6% during the 1st quarter. Vanguard Group Inc. now owns 928,768 shares of the company’s stock worth $15,678,000 after purchasing an additional 96,196 shares in the last quarter. Geode Capital Management LLC increased its position in American Renal Associates Holdings by 2.9% during the 1st quarter. Geode Capital Management LLC now owns 77,726 shares of the company’s stock worth $1,312,000 after purchasing an additional 2,180 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in American Renal Associates Holdings by 7.1% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 38,847 shares of the company’s stock worth $656,000 after purchasing an additional 2,565 shares in the last quarter. Bank of America Corp DE increased its position in American Renal Associates Holdings by 21.6% during the 1st quarter. Bank of America Corp DE now owns 29,837 shares of the company’s stock worth $504,000 after purchasing an additional 5,296 shares in the last quarter. Finally, Acadian Asset Management LLC increased its position in American Renal Associates Holdings by 46.7% during the 2nd quarter. Acadian Asset Management LLC now owns 51,102 shares of the company’s stock worth $948,000 after purchasing an additional 16,271 shares in the last quarter. 92.91% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/25/american-renal-associates-holdings-inc-ara-earns-outperform-rating-from-leerink-swann.html.

About American Renal Associates Holdings

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

The Fly

Receive News & Stock Ratings for American Renal Associates Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc and related stocks with our FREE daily email newsletter.